News headlines about Interpace Diagnostics Group (NASDAQ:IDXG) have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Interpace Diagnostics Group earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned media coverage about the business services provider an impact score of 44.6216569760163 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news headlines that may have impacted Accern’s rankings:
- 13G Filing: Sabby Capital and Interpace Diagnostics Group Inc. (IDXG) (feedproxy.google.com)
- Interpace Diagnostics Recognized as One of the Top 20 Bioinformatics Solutions Providers – GlobeNewswire (press release) (globenewswire.com)
- What Does Interpace Diagnostics Group Inc’s (NASDAQ:IDXG) Share Price Indicate? (finance.yahoo.com)
- Shedding Light on Comprehensive Profitability Analysis: ABB Ltd (NYSE:ABB), Interpace Diagnostics Group, Inc … – Investing News Update (investingbizz.com)
- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) – Is P/E Ratio Alarming? – Nasdaq Journal (press release) (nasdaqjournal.com)
Several analysts have recently issued reports on the stock. Maxim Group reissued a “buy” rating and set a $5.00 price objective on shares of Interpace Diagnostics Group in a research note on Tuesday, November 14th. ValuEngine raised shares of Interpace Diagnostics Group from a “strong sell” rating to a “sell” rating in a research note on Monday, September 11th.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Interpace Diagnostics Group (IDXG) Share Price” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.com-unik.info/2018/01/09/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-interpace-diagnostics-group-idxg-share-price.html.
Interpace Diagnostics Group Company Profile
Interpace Diagnostics Group, Inc, formerly PDI, Inc, is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management.
What are top analysts saying about Interpace Diagnostics Group? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Interpace Diagnostics Group and related companies.